543635 Stock Overview
Operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Piramal Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹252.60 |
| 52 Week High | ₹307.85 |
| 52 Week Low | ₹114.45 |
| Beta | 0.10 |
| 1 Month Change | 1.08% |
| 3 Month Change | 14.09% |
| 1 Year Change | 79.79% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 31.73% |
Recent News & Updates
Recent updates
Shareholder Returns
| 543635 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 1.3% | 0.8% | -4.2% |
| 1Y | 79.8% | 39.7% | 19.1% |
Return vs Industry: 543635 exceeded the Indian Pharmaceuticals industry which returned 39.7% over the past year.
Return vs Market: 543635 exceeded the Indian Market which returned 19.1% over the past year.
Price Volatility
| 543635 volatility | |
|---|---|
| 543635 Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in IN Market | 9.0% |
| 10% least volatile stocks in IN Market | 4.1% |
Stable Share Price: 543635's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 543635's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 6,719 | n/a | www.piramalpharma.com |
Piramal Pharma Limited operates as a pharmaceutical company in North America, Europe, Japan, India, and internationally. The company offers a portfolio of pharmaceutical products and services through global development and manufacturing facilities and distribution network. It also operates contract development and manufacturing organization that provides services across the spectrum of the drug life cycle, including discovery, development, and commercial manufacturing of drug substances and products; complex hospital generics business which offers inhalation anesthetics, intrathecal therapy for spasticity management, injectable pain and anesthesia drugs, and other generic and specialty products; and India consumer healthcare business comprising analgesics, skin care, vitamin/mineral supplement, kids’ wellness, digestives, women’s health, and hygiene and protection.
Piramal Pharma Limited Fundamentals Summary
| 543635 fundamental statistics | |
|---|---|
| Market cap | ₹334.35b |
| Earnings (TTM) | ₹453.30m |
| Revenue (TTM) | ₹87.04b |
737.6x
P/E Ratio3.8x
P/S RatioIs 543635 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 543635 income statement (TTM) | |
|---|---|
| Revenue | ₹87.04b |
| Cost of Revenue | ₹34.68b |
| Gross Profit | ₹52.36b |
| Other Expenses | ₹51.90b |
| Earnings | ₹453.30m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.34 |
| Gross Margin | 60.15% |
| Net Profit Margin | 0.52% |
| Debt/Equity Ratio | 58.7% |
How did 543635 perform over the long term?
See historical performance and comparisonDividends
0.04%
Current Dividend Yield79%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 09:50 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Piramal Pharma Limited is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kunal Randeria | Axis Capital Limited |
| Prakash Agarwal | Axis Capital Limited |
| Rohit Bhat | Batlivala & Karani Securities India Pvt. Ltd. |